NCT04085289View on ClinicalTrials.gov

A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 20, 2019

Primary Completion Date

May 21, 2020

Study Completion Date

May 21, 2020

Conditions
Healthy
Interventions
DRUG

Galcanezumab

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (1)

20040

HuaShan Hospital Affiliated To Fudan University, Shanghai

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04085289 - A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants | Biotech Hunter | Biotech Hunter